Eisai said that its China holding company Eisai China Holdings will buy 100% of the shares of Liaoning TianYi Biological Pharmaceutical.
Article continues below
Liaoning TianYi Biological Pharma is held by both Xiaojun Zhao, representative director and president of Longyuan Education Industry Investment & Management Groups and Hong Sun.
Under this agreement, the purchase price is RMB 500 million (approximately JPY 9.6 billion based on 1 RMB = 19.2 JPY). This agreement is expected to take effect once the conditions of transfer have been arranged.
Located in the Benxi High-tech Industrial Development Zone, a pharmaceutical cluster comprised of around 100 companies and six universities including ShenYang Pharmaceutical University, TianYi is a generic pharmaceutical company in China that manufactures and markets pharmaceutical products and active pharmaceutical ingredients.
TianYi has manufacturing approval for approximately 90 pharmaceutical products covering a wide range of diseases, including immune modulators, traditional Chinese medicines and treatments for inflammation and pain relief, dementia, gastritis, intestinal disorders, diabetes as well as chronic arterial occlusion.
In addition, TianYi possesses the latest production line and technology which is compliant with China's GMP (Good Manufacturing Practice) standards to enable the handling of various different formulations such as tablets, capsules, granules, liquid medicines and freeze dried injectables.
The China pharmaceutical market is the second largest in the world after the United States, and despite China experiencing a slowdown in economic growth, is forecasted to maintain strong growth into the future due to substantial expansion via the rapid aging of the population and the government's policies to improve access to medicines.
In particular, even higher growth is expected for generic pharmaceuticals that will make up the majority of prescriptions in small and medium sized cities in inland and regional areas as well as small and medium sized hospitals which have had inadequate access to medicines until now.
Meanwhile there is strong demand from the government for generic pharmaceuticals with a high level of quality on par with branded pharmaceuticals. The stable supply of high quality pharmaceuticals from TianYi's GMP compliant facility under Eisai's strict quality management and quality assurance system will be able to meet the needs of the China pharmaceutical market.
Through this acquisition, Eisai will enter the generic pharmaceutical business in China in addition to expanding its existing business focused on new medicines.
By further strengthening its business platform foundation established over 25 years of doing business in China and providing a stable supply of high quality generic pharmaceuticals, Eisai will be able to fulfill an even wider range of medical needs in China.
Furthermore, by establishing a business base in Benxi after Suzhou and Shanghai, Eisai will strengthen its collaboration with academia in the Benxi pharmaceutical cluster as well as explore opportunities for further growth.
Eisai will continue to further contribute to increasing the benefits for a greater number of patients and their families throughout China.
In addition, the signing of this agreement will have a minor impact on the consolidated result forecasts for the period ended March 30, 2016. ■